Neuware - Proteomics: A Promising Approach for Cancer Research Volume 2 Proteome signaling dysregulation in cancer, therapeutic interventions, and future perspectives provides an updated overview of scientific knowledge, achievements, and findings in the field of cancer proteomics. The field of cancer proteomics is very dynamic, with emerging trends specifically related to clinical solutions. The book content was developed to help readers get up to speed on the topic and easily apply learnings into research or clinical practice.Volume 2 covers proteome signaling, their dysregulation to therapeutics options and future prospects in 17 different signaling pathways. It capitalizes the enormous interest in proteomics among academics and gives new viewpoints on this topic in cancer treatment. It is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of proteomics in cancer research and treatment.

N� de ref. del art�culo 9780443239083

Contactar al vendedor

Denunciar este art�culo

Detalles bibliogr�ficos

T�tulo: Proteomics: A Promising Approach for Cancer Research : Proteome Signaling Dysregulation in Cancer, Therapeutic Interventions, and Future Perspectives, Volume 2
Editor: Elsevier Science Publishing Co Inc Jan 2026
Fecha de publicaci�n: 2026
Idioma: Ingl�s
ISBN 10: 0443239088
ISBN 13: 9780443239083
Encuadernaci�n: Taschenbuch
Estado: Neu
Dimensiones: 229�mil�metros de ancho por 152 de alto por 32 de largo
Peso: 450 gramos

Acerca de

Sinopsis

Proteomics: A Promising Approach for Cancer Research Volume 2 Proteome signaling dysregulation in cancer, therapeutic interventions, and future perspectives provides an updated overview of scientific knowledge, achievements, and findings in the field of cancer proteomics. The field of cancer proteomics is very dynamic, with emerging trends specifically related to clinical solutions. The book content was developed to help readers get up to speed on the topic and easily apply learnings into research or clinical practice. Volume 2 covers proteome signaling, their dysregulation to therapeutics options and future prospects in 17 different signaling pathways. It capitalizes the enormous interest in proteomics among academics and gives new viewpoints on this topic in cancer treatment. It is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of proteomics in cancer research and treatment.

Acerca de los autores

Muneeb U Rehman (Ph.D.) is a Faculty member at College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. He holds a doctorate in Toxicology (specialization in cancer biology and natural product research) from Jamia Hamdard, New Delhi, India. Dr. Rehman has more than 10 years of research and teaching experience in the field of toxicology, cancer biology, natural product pharmacology and pharmacogenomics. He is the recipient of several national and international fellowships and awards. He has published more than 100 research papers in peer-reviewed, international journals, and has 5 edited books and 30 book chapters. Dr. Rehman is on the editorial boards and is a reviewer of several high-impact, international scientific journals. He is also a life member of various international societies and organizations. Currently, Dr. Rehman is engaged in studying the molecular mechanisms of cancer prevention by natural products and the role of pharmacogenomics and toxicogenomics in evaluating the effectiveness and safety of drugs.

Sabhiya Majid, Ph.D. is a Professor and Chairperson of the Department of Biochemistry, Govt. Medical College Srinagar (GMC Sgr.), J&K, India. Prof. Majid has 30 years of experience in teaching, research and diagnostic biochemistry, having published around 100 research papers in journals of repute, many books and 12 book chapters. She has been the recipient of several fellowships, awards and grants from various reputed funding agencies. She has been the nodal officer and implemented various research and infrastructure development schemes including Fund for Improvement of Science & Technology Infrastructure, Department of Science & Technology, Govt. of India. She is a member of several scientific associations and boards of undergraduate, postgraduate and research studies. She is on the reviewer panel of a number of online peer-reviewed journals. Having moved on from her doctoral work on nutritional modulation of carcinogenesis to understanding the molecular basis of various disease processes, her current research focuses on non invasive cancer markers.

Shafat Ali (Ph.D.) pursued his BSc. from University of Kashmir and Masters in Zoology from Barkatullah Vishwavidyalaya, India. Currently he is engaged in research work for last 5 years at Cytogenetics and Molecular Biology Laboratory, Centre of Research for Development, University of Kashmir, Department of Biochemistry, Government Medical College, Srinagar, Jammu and Kashmir, and ICMR funded Multidisciplinary Research Unit, Government Medical College, Srinagar, Jammu and Kashmir, India, with specialization in the field of reproductive immunogenetics, cytokine biology, gynaecology and obstetrics, molecular biology, cancer biology and cytogenetics. He has 5 years of research experience and 5 years of teaching experience. He has more than 20 book chapters, several edited books and numerous peer-reviewed, international research publications to his credit. Mr. Ali is also the reviewer of many reputed international journals. Presently, Mr. Ali is involved in studying immunogenetic mechanisms involved in recurrent pregnancy loss

Dr. Yahya F. Jamous is a Saudi pharmaceutical scientist and researcher who works at the moment at Wellness and Preventive Medicine Institute, King Abdulaziz City of Science and Technology (KACST), Riyadh. He has been in the research and teaching field of over 15 years has an excellent history of scientific publications in pharmaceutical biotechnology, nanotechnology, and molecular pharmacology.

Dr. Jamous has served KACST in various high-ranking academic and administrative roles, such as Associate Research Professor, Assistant Research Professor, Acting Director of National Partnerships, and a former Director of the National Vaccines and Bioprocessing Centre (NVBC) in support of programs that go in line with Saudi Vision 2030.

He has a PhD in Molecular Pharmacology at ETH Zurich in new therapeutic targets in heart failure and MSc and BSc degrees in Pharmaceutical Sciences at King Saud University. Dr. Jamous is a licensed Consultant of Pharmaceutical Sciences.

"Sobre este t�tulo" puede pertenecer a otra edici�n de este libro.

Descripci�n de la librer�a

Das Unternehmen AHA-BUCH GmbH: Seit der Gr�ndung von AHA-BUCH im Juli 2005 ist unser Hauptziel, zufriedenen Kunden so schnell und so preisg�nstig wie m�glich ihren B�cherwunsch zu erf�llen. Unsere Firma besch�ftigt 16 Mitarbeiter, die nur ein Ziel kennen: den Kunden und seine W�nsche! Auf �ber 3700 m2 Fl�che haben wir �ber 100.000 B�cher, Modernes Antiquariat und Spiele auf Lager.

Ver la p�gina web de la librer�a

Informaci�n empresarial del vendedor

AHA-BUCH GmbH
Garlebsen 48, Einbeck, 37574, Germany

Condiciones de venta y env�o

Condiciones de venta

T�rminos y Condiciones Generales e Informaci�n del Cliente / Pol�tica de Privacidad

I. T�rminos y Condiciones Generales

� 1 Disposiciones b�sicas

(1)Los siguientes t�rminos y condiciones se aplican a todos los contratos que celebre con nosotros como proveedor (AHA-BUCH GmbH) a trav�s de las plataformas de Internet AbeBooks y/o ZVAB. A menos que se acuerde lo contrario, se objetar� la inclusi�n de cualquiera de sus propios t�rminos y condiciones utilizados por usted.
(2)Un consumidor en el sentid...

M�s informaci�n

Derecho al desistimiento

Si es un consumidor, puede rescindir el contrato de acuerdo con lo siguiente. Por consumidor se entiende cualquier persona f�sica que act�e con fines ajenos a su actividad comercial, empresarial, oficio o profesi�n.

Informaci�n sobre el derecho de desistimiento

Derecho legal de desistimiento

Tiene derecho a rescindir este contrato en un plazo de 14 d�as sin dar ning�n motivo.

El periodo de desistimiento vencer� a los 14 d�as desde que usted, o un tercero que no sea el transportista e indicado por usted, adquiera la posesi�n f�sica del �ltimo bien o del �ltimo lote o pieza.

Para ejercer el derecho de desistimiento, complete de forma electr�nica y env�e una declaraci�n clara en nuestro sitio web, desde "Mis compras" en "Mi cuenta". Le enviaremos sin demora un acuse de recibo de dicho desistimiento a trav�s de un soporte duradero (por ejemplo, por correo electr�nico).

Para cumplir con el plazo de desistimiento, basta con que env�e su comunicaci�n relativa al ejercicio del derecho de desistimiento antes de que venza el periodo de desistimiento.

Efectos del desistimiento

Si rescinde este contrato, le reembolsaremos todos los pagos que hayamos recibido de usted, incluidos los gastos de env�o (excepto los gastos adicionales que surjan si elige un tipo de env�o que no sea el tipo de env�o est�ndar m�s econ�mico que ofrecemos).

Podemos hacer una deducci�n del reembolso por la p�rdida de valor de cualquier bien suministrado, si la p�rdida es el resultado de una manipulaci�n innecesaria por su parte.

Efectuaremos el reembolso sin demoras indebidas y, a m�s tardar, 14 d�as despu�s de que se nos informe de su decisi�n de rescindir este contrato.

Efectuaremos el reembolso utilizando el mismo medio de pago que utiliz� para la transacci�n inicial, a menos que haya acordado expresamente lo contrario; en cualquier caso, no incurrir� en ning�n cargo como resultado de dicho reembolso.

Podremos retener el reembolso hasta que hayamos recibido los bienes o hasta que nos haya presentado una prueba de que los ha devuelto, lo que ocurra primero.

Deber� devolver los bienes o entregarlos a AHA-BUCH GmbH, Einbeck, Germany, sin demoras indebidas y, en cualquier caso, en un plazo m�ximo de 14 d�as a partir del d�a en que nos comunique su desistimiento del presente contrato. El plazo se cumple si devuelve la mercanc�a antes de que venza el periodo de 14 d�as. Tendr� que asumir los gastos directos de devoluci�n de los bienes. Usted solo es responsable de la disminuci�n del valor de los bienes como resultado de una manipulaci�n distinta a la necesaria para establecer la naturaleza, las caracter�sticas y el funcionamiento de los bienes.

Excepciones al derecho de desistimiento

El derecho de desistimiento no se aplica a lo siguiente:

La entrega de peri�dicos, diarios o revistas, con la excepci�n de los contratos de suscripci�n; y
El suministro de contenido digital que no se proporcione en un soporte tangible (por ejemplo, en un CD o DVD) si, al hacer el pedido, acept� que pod�amos empezar a entregarlo y que no podr�a desistir una vez iniciada la entrega.

Condiciones de env�o

Enviamos su pedido despu�s de recibirlos
para art�culos disponibles las �ltimas 24 horas,
para art�culos con suministro nocturno a m�s tardar 48 horas.
En caso de que necesitemos pedir un art�culo a nuestro proveedor, nuestro tiempo de env�o depende de la fecha de recepci�n de los art�culos, pero los art�culos se enviar�n el mismo d�a.

Nuestro objetivo es enviar los art�culos pedidos de la manera m�s r�pida, pero tambi�n m�s eficiente y segura a nuestros clientes.

Tarifas de env�o de Alemania a Estados Unidos de America

Tarifas de env�o de Alemania a Estados Unidos de America
Cantidad del pedido	De 30 a 40 d�as h�biles	De 7 a 14 d�as h�biles
Primer art�culo	EUR 62.25	EUR 72.25

Los plazos de entrega los establecen los vendedores y var�an seg�n el transportista y la ubicaci�n. Los pedidos que pasan por la aduana pueden sufrir retrasos y los compradores son responsables de los aranceles o tarifas asociadas. Los vendedores pueden ponerse en contacto con usted en relaci�n con cargos adicionales para cubrir cualquier aumento en los costes de env�o de los art�culos.

Informaci�n detallada sobre el vendedor